DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Corbin AS, La Rosée P, Stoffregen E, et al. Several Bcr-Abl kinase
domain mutants associated with imatinib mesylate resistance
remain sensitive to imatinib. Blood, 2003, 101:4611–4614.
Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention
of dilated cardiomyopathy. Nat Med, 2002, 8:459–465.
DeMatteo R, Ballman KV, Antonescu CR, et al. Adjuvant imatinib
mesylate after resection of localised, primary gastrointestinal
stromal tumour: A randomised, double-blind,
placebo-controlled trial. Lancet, 2009, 373:1097–1104.
Dowell JA, Korth-Bradley J, Liu H, et al. Pharmacokinetics of
gemtuzumab ozogamicin, and antibody-targeted chemotherapy
agent for the treatment of patients with acute myeloid
leukemia in first relapse. J Clin Pharmacol, 2001, 41:
1206–1214.
Druker BJ. Imatinib as a paradigm of targeted therapies. Adv
Cancer Res, 2004, 91:1–30.
Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation
signature predicts response to lenalidomide in myelodysplastic
syndrome. PLoS Med, 2008, 5:e35.
Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification
leads to gefitinib resistance in lung cancer by activating
ERBB3 signaling. Science, 2007, 16:1039–1043.
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clearcell
renal-cell carcinoma. N Engl J Med, 2007, 356:125–134.
Fabian MA, Biggs WH III, Treiber DK, et al. A small moleculekinase
interaction map for clinical kinase inhibitors. Nat
Biotechnol, 2005, 23:329–336.
Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl
J Med, 1971, 285:1182-1186.
Foss FM, Bacha P, Osann KE, et al. Biological correlates of
acute hypersensitivity events with DAB(389)IL-2 (denileukin
diftitox, ONTAK) in cutaneous T-cell lymphoma: Decreased
frequency and severity with steroid premedication. Clin
Lymphoma, 2001, 1:298–302.
Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet,
2004, 363:1802–1811.
Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H)
and CHOP chemotherapy as first-line treatment of peripheral
T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie
Innovative nei Linfomi) prospective multicenter trial. Blood,
2007, 110:2316–2323.
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus
capecitabine for HER2-positive advanced breast cancer. N Engl
J Med, 2006, 355:2733–2743.
Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities
and their management. Ann Pharmacother, 2009,
43:490–501.
Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations
and imatinib response in patients with metastatic gastrointestinal
stromal tumor. J Clin Oncol, 2003, 21:4342–4349.
Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary
kinase genotypes correlate with the biological and clinical
activity of sunitinib in imatinib-resistant gastrointestinal
stromal tumor. J Clin Oncol, 2008, 26:5352–5359.
Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its
analogs overcome drug resistance of human multiple myeloma
cells to conventional therapy. Blood, 2000, 96:2943–2950.
Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared
with chlorambucil as first-line therapy for chronic lymphocytic
leukemia. J Clin Oncol, 2007, 25:5616–5623.
Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab
and iodine-131 tositumomab (bexxar) in B-cell
lymphoma, progressive after rituximab. J Clin Oncol, 2005,
23:712–719.
Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML
patients responding to treatment with tyrosine kinase inhibitors:
Review and recommendations for harmonizing current methodology
for detecting BCR-ABL transcripts and kinase domain
mutations and for expressing results. Blood, 2006, 108:28–37.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus
irinotecan, fluorouracil, and leucovorin for metastatic colorectal
cancer. N Engl J Med, 2004, 350:2335–2342.
Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies
for metastatic renal cell carcinoma: An overview of toxicity
and dosing strategies. Oncologist, 2008, 13:1084–1096.
Hynes NE, Lane HA. ERBB receptors and cancer: The complexity
of targeted inhibitors. Nat Rev Cancer, 2005, 5:341–354.
Jain RK. A new target for tumor therapy. N Engl J Med, 2009,
360:2669–2671.
Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized
phase II trial comparing bevacizumab plus carboplatin and
Paclitaxel with carboplatin and paclitaxel alone in previously
untreated locally advanced or metastatic non-small-cell lung
cancer. J Clin Oncol, 2004, 22:2184–2191.
Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA
approval for the treatment of multiple myeloma progressing
on prior therapy. Oncologist, 2003, 8:508–513.
Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinibresistant
CML and Philadelphia chromosome-positive ALL.
N Engl J Med, 2006, 354:2542–2551.
Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib
mesylate therapy in newly diagnosed Philadelphia
chromosome–positive chronic phase chronic myeloid
leukemia. Blood, 2004, 103:2873–2878.
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations
and benefit from cetuximab in advanced colorectal cancer.
N Engl J Med, 2008, 359:1757–1765.
Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab
(Campathe-1H) in patients who have failed fludarabine:
Results of a large international study. Blood, 2002,
99:3554–3561.
Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and
resistance of non-small-cell lung cancer to gefitinib. N Engl J
Med, 2005, 352:786–792.
Konrad MW, Hemstreet G, Hersh EM, et al. Pharmacokinetics of
recombinant interleukin 2 in humans. Cancer Res, 1990, 50:
2009–2017.
Kranick SM, Mowry EM, Rosenfeld MR. Progressive multifocal
leukoencephalopathy after rituximab in a case of non-
Hodgkin lymphoma. Neurology, 2007, 69:704–706.
Kumar S, Kimlinger TK, Lust JA, et al. Expression of CD52 on
plasma cells in plasma cell proliferative disorders. Blood,
2003, 102:1075–1077.
Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide
down-regulates the CD20 antigen and antagonizes direct and
antibody-dependent cellular cytotoxicity of rituximab on primary
chronic lymphocytic leukemia cells. Blood, 2008,
112:5180–5189.
Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the
efficacy and safety of gemtuzumab ozogamicin (mylotarg) in
1751
CHAPTER 62
TARGETED THERAPIES: TYROSINE KINASE INHIBITORS, MONOCLONAL ANTIBODIES, AND CYTOKINES